Showing data about arrow_drop_down
Update
- The pharma industry - R&D
- The pharma industry in figures - Economy
- The pharma industry in figures - Employment
- The pharma industry in figures - Healthcare
- Value to patients
- Value to healthcare systems
- Value to the economy
- Value to society
- Medicines cost in context
- Innovation
- Pharmaceutical R&D expenditure in Europe, USA and Japan
- R&D process
- R&D in Europe
- Allocation of R&D investments
- New chemical or biological entities
- Estimated costs of bringing a new entity to market
- Pharmaceutical R&D expenditure - Annual growth rate (%)
- R&D intensity
- Impact on the European economy
- Geographical breakdown of sales of new medicines
- R&D expenditure in Europe, USA and Japan
- Parallel imports
- Production
- World pharmaceutical market
- Market value
- VAT rates
- Generics
- Imports and exports
- Trade balance (by country)
- Trade balance - high technology sectors
- EU main pharmaceutical trading partners
- Employment in the pharmaceutical industry (by country)
- Employment in the pharmaceutical industry (by year)
- Employment in pharmaceutical R&D
- Total spending on healthcare
- Payment for pharmaceuticals
- Causes of death by major disease areas
- Breakdown of health expenditure
- New medicines
- Cancer mortality
- Life expectancy
- Hep C - cure rates
- Chronic diseases - impact
- Vaccines - impact
- HIV - death rates
- Health gains and savings
- The added value of medicines
- Industry contribution to European economy
- Innovative treatments
- Ageing population
- Chronic disease
- New medicines
Medicine use yields significant health gains and savings in other parts of healthcare systems: the case of HEP C
Treatment with bDMARDs does not only lead to symptom reduction but also greater disease control and less progression of joint damage
1. EMERY, ET AL. 2008
2. RHEUMATOLOGY USHERBROOKE, ACCESSED AUGUST ’22
3. SALAFFI ET AL. 2019
https://www.efpia.eu/media/676700/allowing-ra-patients-to-live-a-normal-life-with-biologics.pdf